In MSI-H CRC patients, the high response rate to the ICP blockade appears due to a higher tumor mutational burden, the presence of neoantigens and consequent infiltration by CD8+ (TC, cytotoxic T lymphocyte) CTL and higher expression levels of ICPs (5). This evidence concerns the gene CD8A and neoplasm.